Clinical management of vascular retinopathy in diabetic patients and the impact on their QoL: REDIMA Study

Le résumé fourni par la source

Abstract Purpose to determine the clinical management of vascular retinopathy (VR) in diabetic patients and the impact on their QoL. Determine the progression of the VR in the 6 months after diagnosis and evaluate the correlation between the evolution of the systemic disease and progression of the VR Methods Patients with type 1 or 2 diabetes, ≥18 years, with new diagnosed vascular retinopathy (without treatment and with clinically significant macular edema) were included in this ongoing, epidemiological, 6‐months prospective, multicentric study Results Data of 219 patients were evaluated at baseline. Mean age was 64 ± 11.8 years, 179 (85.2%) had type 2 diabetes and 31 (14.8%) type 1. 93.9% (200/213) presented diabetic retinopathy (DR), 71.2% (151/212) had bilateral macular edema, 5.7% (11/194) showed central retinal vein occlusion, and 10.2% (18/177) presented branch retinal vein occlusion. Surgical treatment for retinal pathology was started with laser in 64.4% of patients (112/174), panphotocoagulation in 41.1% (58/141) and vitrectomy for 9.1% (12/132) and medical treatment with sodium pegaptanib in 61 subjects (29.8%), triamcinolone in 19 (9.3%), in 8 (3.9%) with bevacizumab and in 4 (2.0%) with ranibizumab. 81.3% (170/209) were considered to have cardiovascular risk. Mean score for General Health subscale (NEI VFQ‐25;100 best; 0 worst) was 37.4±19, and 56.8±16.4 for General Vision subscale Conclusion Data recording is continuing to study the evolution after 6 months

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.